ZYPH 0907Alternative Names: ZYPH0907
Latest Information Update: 16 Jul 2016
At a glance
- Originator Zydus Cadila
- Mechanism of Action Parathyroid hormone receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Osteoporosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Osteoporosis(In volunteers) in India (PO)
- 15 Apr 2012 Phase-I clinical trials (in volunteers) in Osteoporosis in India (PO)